Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19418006 | 0.72 | GABRA1 (0.37) | ARESR1ESR2 | |
| SCHEMBL22396850 | 0.71 | ENPP2 (0.45) | ENPP2ARCCR2 | |
| SCHEMBL1128576 | 0.71 | ENPP2 (0.45) | ENPP2ARCCR2ESR1ESR2 | |
| SCHEMBL16904912 | 0.69 | PTGS2 (0.33) | ADRB2 | |
| SCHEMBL16896662 | 0.69 | TAAR1 (0.41) | ENPP2ADRB2 | |
| SCHEMBL15109955 | 0.68 | CASP1 (0.41) | ENPP2ESR1ESR2 | |
| SCHEMBL1472949 | 0.67 | GABRA1 (0.46) | ARESR1ESR2 | |
| SCHEMBL18589788 | 0.67 | TAAR1 (0.39) | ADRB2 | |
| SCHEMBL16904910 | 0.66 | SMN1; SMN2 (0.33) | ADRB2 | |
| SCHEMBL16896814 | 0.66 | CYP3A4 (0.44) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | RGENIX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | INSPIRNA, INC. | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669296-B2 | LXR agonists and uses thereof | NR1H3, NR1H2, NR1H4 | ENPP2 190/4885AR 206/4885CCR2 450/4885 |
| US-20170066791-A1 | LXR AGONISTS AND USES THEREOF | NR1H3, NR1H2, NR1H4 | ENPP2 190/4885AR 206/4885CCR2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.